Cellid, Company Description

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies.

It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens.

The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo, a customized immunotherapeutic vaccine; and COVID-19 prevention vaccines.

Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.

Cellid, Co., Ltd.

Country	South Korea
Founded	2006
Industry	Biological Products, Except Diagnostic Substances
CEO	Yuil Kang Chang

Contact Details

Address: 142 dong Seoul National University Seoul, 08826 South Korea
Phone	82 7 0423 73415
Website	cellid.co.kr

Stock Details

Ticker Symbol	299660
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Yuil Kang Chang	Chief Executive Officer
Kim Minsoo	Chief Financial Officer
Kim Minsoo	Head of Investor Relations